Anti-obesity medications linked to reduced alcohol consumption in weight loss study
A recent study published in JAMA Network Open has revealed intriguing insights into the behavioural effects of anti-obesity medications (AOMs), particularly their impact on alcohol consumption. Conducted within the WeightWatchers (WW) Clinic telehealth weight management programme, the research examined alcohol use patterns among participants who initiated AOMs, with nearly half reporting a decrease in alcohol consumption.
How Do Anti-Obesity Medications Impact Alcohol Use?
AOMs, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), are well-established for promoting significant weight loss. However, emerging evidence highlights their potential benefits beyond weight management. GLP-1 RAs have been associated with reduced incidence and recurrence of alcohol use disorder, hinting at their broader therapeutic scope.
Understanding the mechanisms underpinning these effects is vital. Comparative studies examining how different AOMs influence alcohol use could pave the way for enhanced approaches to weight management and addiction treatment. This research underscores the need for further exploration of the behavioural impacts of these medications.
Study Overview
This study included participants from the WW telehealth weight management programme who had initiated an AOM between January 2022 and August 2023 and refilled their prescription between October and November 2023. Participants using AOMs prior to enrolment or with a history of bariatric surgery were excluded, as these factors may alter alcohol use disorder risk.
The study adhered to rigorous ethical and reporting standards, receiving approval from the Henry Ford Health institutional review board and following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Data were deidentified, negating the need for informed consent.
Participants completed baseline surveys capturing demographic details, including age, sex assigned at birth, race, ethnicity, height, weight, and weekly alcohol consumption. Their body mass index (BMI) was calculated from self-reported height and weight. Follow-up surveys assessed changes in alcohol use at the time of AOM refill. Statistical analyses, including multivariate logistic regression, evaluated alcohol use trends, with R software used for computations.
Findings
The study included 14,053 participants, 86% of whom were women, with an average age of 43.2 years and a mean BMI of 36. Most participants (86%) were prescribed second-generation GLP-1 RAs, such as tirzepatide or semaglutide, while others received first-generation GLP-1 RAs, bupropion/naltrexone, or metformin. Participants represented a spectrum of obesity classes: 41.3% were classified as obesity class I, 26% as class II, and 21% as class III.
At baseline, 53.3% of participants reported alcohol use. Among this group:
- 45.3% reduced alcohol consumption after starting an AOM.
- 52.4% reported no change in their drinking habits.
- 2.3% experienced an increase in alcohol use.
Across all participants, 24.2% experienced a reduction in alcohol use. Individuals with higher obesity classes and greater baseline alcohol consumption were more likely to report reduced alcohol use. Participants prescribed bupropion/naltrexone showed a higher likelihood of reducing alcohol consumption compared to those on metformin. However, after adjusting for weight loss, this association lost statistical significance, suggesting that reductions in alcohol use may be partly mediated by weight loss rather than medication-specific effects.
On average, participants experienced a 12.7% reduction in initial body weight over approximately 224.6 days between AOM initiation and follow-up.
Interpreting the Results
The findings point to several potential mechanisms driving reduced alcohol use. Pharmacologically, naltrexone, a component of some AOMs, is known to suppress alcohol cravings. GLP-1 RAs may also diminish the rewarding effects of alcohol consumption. Additionally, behavioural factors associated with weight management programmes, such as encouragement to limit alcohol for calorie control and cognitive restraint, likely contributed to these outcomes.
Conclusion
This study highlights a notable secondary benefit of AOMs: their potential to support reduced alcohol consumption among individuals managing obesity. Nearly half of participants who consumed alcohol at baseline reported a decrease in their intake after starting AOM therapy. These findings offer promising implications for the dual role of AOMs in addressing obesity and its associated behavioural challenges. Further research is essential to deepen our understanding of these interactions and optimise therapeutic approaches in weight management and addiction care.
